Works matching IS 10196439 AND DT 2022 AND VI 60 AND IP 4

Results: 12

Antagonism of the transient receptor potential melastatin-2 channel leads to targeted antitumor effects in primary human malignant melanoma cells.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5333
By:
- McKamey, Shelby G.;
- Jira, Lukas R.;
- Tweed, Christopher M.;
- Blake, Steven D.;
- Powell, Daniel P.;
- Daghistani, Ayah T.;
- Koh, David W.
Publication type:
Article
Correlation of SARS-CoV-2 to cancer: Carcinogenic or anticancer? (Review).
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5332
By:
- Li, Ying-Shuang;
- Ren, Hua-Cheng;
- Cao, Jian-Hua
Publication type:
Article
Discovery of a potent cytotoxic agent that promotes G<sub>2</sub>/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5331
By:
- Nuth, Manunya;
- Benakanakere, Manjunatha R.;
- Ricciardi, Robert P.
Publication type:
Article
High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1<sup>low/negative</sup> non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5330
By:
- Wang, Lina;
- Xu, Xiaolong;
- Shang, Bin;
- Sun, Jian;
- Liang, Bin;
- Wang, Xingguang;
- You, Wenjie;
- Jiang, Shujuan
Publication type:
Article
Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5329
By:
- Schneider, Marc A.;
- Richtmann, Sarah;
- Gründing, Anna R.;
- Wrenger, Sabine;
- Welte, Tobias;
- Meister, Michael;
- Kriegsmann, Mark;
- Winter, Hauke;
- Muley, Thomas;
- Janciauskiene, Sabina
Publication type:
Article
Spine-specific downregulation of LAPTM5 expression promotes the progression and spinal metastasis of estrogen receptor-positive breast cancer by activating glutamine-dependent mTOR signaling.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5337
By:
- Meng, Qingbing;
- Zhou, Lei;
- Liang, Haifeng;
- Hu, Annan;
- Zhou, Hao;
- Zhou, Jian;
- Zhou, Xiaogang;
- Lin, Hong;
- Li, Xilei;
- Jiang, Libo;
- Dong, Jian
Publication type:
Article
An emerging role of radiation-induced exosomes in hepatocellular carcinoma progression and radioresistance (Review).
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5336
By:
- Fan, Qing;
- Yu, Yue;
- Zhou, Yueling;
- Zhang, Sheng;
- Wu, Chunli
Publication type:
Article
DYRK1A suppression attenuates HIF-1α accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5335
By:
- Zhang, Chong;
- Wu, Lin-Wen;
- Li, Zhi-Di;
- Zhang, Man-Man;
- Wu, Jie;
- Du, Fei-Hua;
- Zeng, Ling-Hui;
- Li, Yang-Ling
Publication type:
Article
LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5334
By:
- Pu, Feifei;
- Liu, Jianxiang;
- Jing, Doudou;
- Chen, Fengxia;
- Huang, Xin;
- Shi, Deyao;
- Wu, Wei;
- Lin, Hui;
- Zhao, Lei;
- Zhang, Zhenhao;
- Lv, Xiao;
- Wang, Baichuan;
- Zhang, Zhicai;
- Shao, Zengwu
Publication type:
Article
circ-LRP6 contributes to osteosarcoma progression by regulating the miR-141-3p/HDAC4/HMGB1 axis.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5328
By:
- Yu, Yali;
- Dong, Guixiang;
- Li, Zijun;
- Zheng, Yan;
- Shi, Zhisong;
- Wang, Guanghui
Publication type:
Article
Knockdown of SNHG15 suppresses renal cell carcinoma proliferation and EMT by regulating the NF-κB signaling pathway.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5326
By:
- Du, Yang;
- Kong, Chuize;
- Zhu, Yuyan;
- Yu, Meng;
- Li, Zeliang;
- Bi, Jianbin;
- Li, Zhenhua;
- Liu, Xiankui;
- Zhang, Zhe;
- Yu, Xiuyue
Publication type:
Article
HepaCAM-PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation.
Published in:
International Journal of Oncology, 2022, v. 60, n. 4, p. N.PAG, doi. 10.3892/ijo.2022.5327
By:
- He, Zhenting;
- Gao, Yingying;
- Li, Ting;
- Yu, Chaowen;
- Ou, Liping;
- Luo, Chunli
Publication type:
Article